Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Duloxetine-Referenced, Fixed-Dose Study Comparing the Efficacy and Safety of 2 Doses (15 and 20 mg) of Lu AA21004 in Acute Treatment of Adults With Major Depressive Disorder

Next Previous
Trial Profile

A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Duloxetine-Referenced, Fixed-Dose Study Comparing the Efficacy and Safety of 2 Doses (15 and 20 mg) of Lu AA21004 in Acute Treatment of Adults With Major Depressive Disorder

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 28 Mar 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Vortioxetine (Primary) ; Duloxetine
  • Indications Major depressive disorder
  • Focus Registrational; Therapeutic Use

Most Recent Events

  • 01 May 2023 Results of pooled analysis from NCT01140906, NCT01153009, NCT01163266, NCT01255787, NCT01488071, published in the Journal of Affective Disorders
  • 01 Sep 2015 Results of meta analysis of pooled data from 9 trials presented at the 28th Annual Congress of the European College of Neuropsychopharmacology
  • 18 May 2013 Results presented at 166th Annual American Psychiatric Association Meeting, according to Takeda Pharmaceutical Company and Lundbeck media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top